The expression of MIF is associated with the clinical severity of various autoimmune diseases and is regulated by several key transcription factors such as ICBP90, Pit‐1, Sp1, and AP‐1.[44] Additionally, elevated Sp1 levels can lead to the degradation of p53 through MDM2‐mediated ubiquitination.[28a] Furthermore, TLR4 agonists have been shown to significantly increase MIF expression through ICBP90, prompting further investigation into the relationship between resistin and MIF. Here, SP1 is linked to autoimmune disease.